Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 173 articles:
HTML format



Single Articles


    July 2021
  1. MURTOLA TJ, Siltari A
    Statins for prostate cancer: when and how much?
    Clin Cancer Res. 2021 Jul 19. pii: 1078-0432.CCR-21-1891.
    PubMed     Abstract available


  2. SARKER D, Dawson NA, Aparicio AM, Dorff TB, et al
    A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kbeta inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2021 Jul 19. pii: 1078-0432.CCR-21-1115.
    PubMed     Abstract available


    June 2021
  3. TURNER PG, Jain S, Cole A, Grey A, et al
    Toxicity and efficacy of concurrent androgen deprivation therapy, pelvic radiotherapy, and radium-223 in patients with de-novo metastatic hormone sensitive prostate cancer.
    Clin Cancer Res. 2021 Jun 29. pii: 1078-0432.CCR-21-0685.
    PubMed     Abstract available


  4. CALAGUA C, Ficial M, Jansen CS, Hirz T, et al
    A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
    Clin Cancer Res. 2021 Jun 24. pii: 1078-0432.CCR-21-0121.
    PubMed     Abstract available


  5. TANG Z, Pilie PG, Geng C, Manyam GC, et al
    ATR inhibitor-induced CDK1-SPOP axis destabilizes PD-L1 and enhances cytotoxicity in prostate cancer.
    Clin Cancer Res. 2021 Jun 24. pii: 1078-0432.CCR-21-1010.
    PubMed     Abstract available


  6. KIM DH, Sun D, Storck WK, Welker Leng KR, et al
    BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
    Clin Cancer Res. 2021 Jun 18. pii: 1078-0432.CCR-20-4968.
    PubMed     Abstract available


  7. SMITH MR, Thomas S, Gormley M, Chowdhury S, et al
    Blood Biomarker Landscape in Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0358.
    PubMed     Abstract available


  8. FONG L, Morris MJ, Sartor O, Higano CS, et al
    A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0063.
    PubMed     Abstract available


  9. ANNALA M, Taavitsainen S, Khalaf DJ, Vandekerkhove G, et al
    Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition.
    Clin Cancer Res. 2021 Jun 3. pii: 1078-0432.CCR-21-1625.
    PubMed     Abstract available


    May 2021
  10. HAMMER S, Schlicker A, Zitzmann-Kolbe S, Baumgart S, et al
    Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC) by a dual mode-of-action in prostate cancer models.
    Clin Cancer Res. 2021 May 25. pii: 1078-0432.CCR-21-0342.
    PubMed     Abstract available


  11. MUNN LL, Stylianopoulos T, Jain NK, Hardin CC, et al
    Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer.
    Clin Cancer Res. 2021;27:2706-2711.
    PubMed     Abstract available


  12. KAWAMOTO K, Okino ST, Place RF, Urakami S, et al
    Editor's Note: Epigenetic Modifications of RASSF1A Gene through Chromatin Remodeling in Prostate Cancer.
    Clin Cancer Res. 2021;27:2665.
    PubMed    


    April 2021
  13. TRUE LD, Chen DL
    How accurately does PSMA inhibitor 18F-DCFPyL-PET-CT image prostate cancer?
    Clin Cancer Res. 2021 Apr 23. pii: 1078-0432.CCR-21-0749.
    PubMed     Abstract available


  14. PRIVE BM, Peters SMB, Muselaers CHJ, van Oort IM, et al
    Lutetium-177-PSMA-617 in low-volume hormone sensitive metastatic prostate cancer, a prospective pilot study.
    Clin Cancer Res. 2021 Apr 21. pii: 1078-0432.CCR-20-4298.
    PubMed     Abstract available


  15. MCKAY RR, Kwak L, Crowdis J, Sperger JM, et al
    Phase 2 multicenter study of enzalutamide in metastatic castration resistant prostate cancer to identify mechanisms driving resistance.
    Clin Cancer Res. 2021 Apr 13. pii: 1078-0432.CCR-20-4616.
    PubMed     Abstract available


    March 2021
  16. PACHYNSKI RK, Kim E, Miheecheva N, Kotlov N, et al
    Single cell spatial proteomic revelations on the multiparametric MRI heterogeneity of clinically significant prostate cancer.
    Clin Cancer Res. 2021 Mar 26. pii: 1078-0432.CCR-20-4217.
    PubMed     Abstract available


  17. VARDAKI I, Corn P, Gentile E, Song JH, et al
    Radium 223 treatment increase immune checkpoint expression in extracellular vesicles from the metastatic prostate cancer bone microenvironment.
    Clin Cancer Res. 2021 Mar 22. pii: 1078-0432.CCR-20-4790.
    PubMed     Abstract available


  18. PALMBOS PL, Daignault-Newton S, Tomlins SA, Agarwal N, et al
    A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone Sensitive Prostate Cancer (mHSPC).
    Clin Cancer Res. 2021 Mar 16. pii: 1078-0432.CCR-21-0024.
    PubMed     Abstract available


  19. FREEDLAND SJ, Allen J, Jarman A, Oyekunle T, et al
    Correction: A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2).
    Clin Cancer Res. 2021;27:1823.
    PubMed    


  20. KAMAT NV, Yu EY, Lee JK
    BiTE-ing into prostate cancer with bispecific T cell engagers.
    Clin Cancer Res. 2021 Mar 11. pii: 1078-0432.CCR-21-0355.
    PubMed     Abstract available


    February 2021
  21. MORRIS MJ, Rowe SP, Gorin MA, Saperstein L, et al
    Diagnostic Performance of (18)F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study.
    Clin Cancer Res. 2021 Feb 23. pii: 1078-0432.CCR-20-4573.
    PubMed     Abstract available


  22. PETRYLAK DP, Loriot Y, Shaffer D, Braiteh F, et al
    Safety and Clinical Activity of Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer: a Phase I Study.
    Clin Cancer Res. 2021 Feb 10. pii: 1078-0432.CCR-20-1981.
    PubMed     Abstract available


  23. TUKACHINSKY H, Madison RW, Chung JH, Gjoerup O, et al
    Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms.
    Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-4805.
    PubMed     Abstract available


  24. LIANG Y, Jeganathan S, Marastoni S, Sharp A, et al
    Emergence of Enzalutamide resistance in prostate cancer is associated with BCL-2 and IKKB dependencies.
    Clin Cancer Res. 2021 Feb 4. pii: 1078-0432.CCR-20-3260.
    PubMed     Abstract available


    January 2021
  25. DEEGEN P, Thomas O, Nolan-Stevaux O, Li S, et al
    The PSMA Targeting Half-Life Extended BiTE((R)) Therapy AMG 160 Has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2021 Jan 27. pii: 1078-0432.CCR-20-3725.
    PubMed     Abstract available


  26. GOLDKORN A, Tangen CM, Plets M, Morrison GJ, et al
    Baseline circulating tumor cell count as a prognostic marker of PSA response and disease progression in metastatic castrate sensitive prostate cancer (SWOG S1216).
    Clin Cancer Res. 2021 Jan 26. pii: 1078-0432.CCR-20-3587.
    PubMed     Abstract available


  27. PAN W, Zhang Z, Kimball H, Qu F, et al
    Abiraterone acetate induces CREB1 phosphorylation and enhances the function of the CBP-p300 complex, leading to resistance in prostate cancer cells.
    Clin Cancer Res. 2021 Jan 25. pii: 1078-0432.CCR-20-4391.
    PubMed     Abstract available


  28. MARSHALL CH, Fu W, Wang H, Park JC, et al
    Randomized phase II trial of sipuleucel-T with or without radium-223 in men with bone-metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2021 Jan 15. pii: 1078-0432.CCR-20-4476.
    PubMed     Abstract available


  29. VEACH D, Storey CM, Lueckerath K, Braun K, et al
    PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates.
    Clin Cancer Res. 2021 Jan 13. pii: 1078-0432.CCR-20-3614.
    PubMed     Abstract available


    December 2020
  30. WANG S, Li J, Hua J, Su Y, et al
    Molecular imaging of prostate cancer targeting CD46 using immunoPET.
    Clin Cancer Res. 2020 Dec 8. pii: 1078-0432.CCR-20-3310.
    PubMed     Abstract available


    November 2020
  31. LOTAN TL, Antonarakis ES
    CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer.
    Clin Cancer Res. 2020 Nov 16. pii: 1078-0432.CCR-20-3877.
    PubMed     Abstract available


  32. DELUCIA DC, Cardillo TM, Ang LS, Labrecque MP, et al
    Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer.
    Clin Cancer Res. 2020 Nov 16. pii: 1078-0432.CCR-20-3396.
    PubMed     Abstract available


    October 2020
  33. AWASTHI S, Berglund AE, Abraham-Miranda J, Rounbehler RJ, et al
    Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer.
    Clin Cancer Res. 2020 Oct 9. pii: 1078-0432.CCR-20-2925.
    PubMed     Abstract available


  34. KARZAI F, Walker SM, Wilkinson S, Madan RA, et al
    Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-Risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is predictive of therapeutic response.
    Clin Cancer Res. 2020 Oct 6. pii: 1078-0432.CCR-20-2344.
    PubMed     Abstract available


    September 2020
  35. CHEN WS, Haynes WA, Waitz R, Kamath K, et al
    Autoantibody landscape in patients with advanced prostate cancer.
    Clin Cancer Res. 2020 Sep 23. pii: 1078-0432.CCR-20-1966.
    PubMed     Abstract available


  36. TRIPATHI A, Supko JG, Gray KP, Melnick Z, et al
    Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib.
    Clin Cancer Res. 2020 Sep 17. pii: 1078-0432.CCR-20-2306.
    PubMed     Abstract available


  37. GAO AC, Armstrong CM, Liu C, Liu L, et al
    Steroid sulfatase stimulates intracrine androgen synthesis and is a therapeutic target for advanced prostate cancer.
    Clin Cancer Res. 2020 Sep 14. pii: 1078-0432.CCR-20-1682.
    PubMed     Abstract available


  38. BORDINI J, Morisi F, Elia AR, Santambrogio P, et al
    Iron induces cell death and strengthens the efficacy of anti-androgen therapy in prostate cancer models.
    Clin Cancer Res. 2020 Sep 14. pii: 1078-0432.CCR-20-3182.
    PubMed     Abstract available


    August 2020
  39. MUNIYAN S, Rachagani S, Parte S, Halder S, et al
    Sildenafil potentiates the therapeutic efficacy of docetaxel in advanced prostate cancer by stimulating NO-cGMP signaling.
    Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-1569.
    PubMed     Abstract available


  40. AUTIO KA, Klebanoff CA, Schaer DA, Kauh JS, et al
    Immunomodulatory Activity of a Colony-Stimulating Factor-1 Receptor Inhibitor in Patients With Advanced Refractory Breast or Prostate Cancer: A Phase 1 Study.
    Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-0855.
    PubMed     Abstract available


    July 2020
  41. SHENDEROV E, Antonarakis ES
    Reimagining vaccines for prostate cancer: Back to the future.
    Clin Cancer Res. 2020 Jul 31. pii: 1078-0432.CCR-20-2257.
    PubMed     Abstract available


  42. GUAN X, Sun D, Lu E, Urrutia JA, et al
    Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Jul 29. pii: 1078-0432.CCR-19-2303.
    PubMed     Abstract available


  43. PARK SY, Na SJ, Kumar M, Mosci C, et al
    Clinical evaluation of (4S)-4-(3-[(18)F]Fluoropropyl)-L-glutamate ((18)F-FSPG) for PET/CT imaging in patients with newly diagnosed and recurrent prostate cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-0644.
    PubMed     Abstract available


  44. AGGARWAL RR, Schweizer MT, Nanus DM, Pantuck AJ, et al
    A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-1707.
    PubMed     Abstract available


  45. KAUR H, Salles DC, Murali S, Hicks JL, et al
    Genomic and Clinical-Pathologic Characterization of ATM-deficient Prostate Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-0764.
    PubMed     Abstract available


  46. HINTZ HM, Gallant JP, Vander Griend DJ, Coleman I, et al
    Imaging Fibroblast Activation Protein Alpha improves diagnosis of metastatic Prostate Cancer with Positron Emission Tomography.
    Clin Cancer Res. 2020 Jul 7. pii: 1078-0432.CCR-20-1358.
    PubMed     Abstract available


    June 2020
  47. PALANISAMY N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, et al
    The MD Anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development.
    Clin Cancer Res. 2020 Jun 23. pii: 1078-0432.CCR-20-0479.
    PubMed     Abstract available


  48. PEREZ-RUIXO C, Ackaert O, Ouellet D, Chien C, et al
    Efficacy and safety exposure-response relationships of apalutamide in patients with non-metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2020 Jun 19. pii: 1078-0432.CCR-20-1041.
    PubMed     Abstract available


  49. RAVI KUMAR AS, Hofman MS
    Mechanistic Insights for Optimizing PSMA Radioligand Therapy.
    Clin Cancer Res. 2020;26:2774-2776.
    PubMed     Abstract available


  50. CURRENT K, Meyer C, Magyar CE, Mona CE, et al
    Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.
    Clin Cancer Res. 2020;26:2946-2955.
    PubMed     Abstract available


  51. WANG B, Liu C, Wei Y, Meng J, et al
    A prospective trial of (68)Ga-PSMA and (18)F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration.
    Clin Cancer Res. 2020 Jun 11. pii: 1078-0432.CCR-20-0587.
    PubMed     Abstract available


  52. KYRIAKOPOULOS CE, Eickhoff J, Ferrari AC, Schweizer MT, et al
    Multicenter Phase 1 Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer.
    Clin Cancer Res. 2020 Jun 8. pii: 1078-0432.CCR-20-0945.
    PubMed     Abstract available


    May 2020
  53. POSADAS EM, Chi KN, de Wit R, de Jonge MJA, et al
    Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase 1b Study.
    Clin Cancer Res. 2020 May 4. pii: 1078-0432.CCR-19-3402.
    PubMed     Abstract available


    April 2020
  54. MALIHI PD, Graf RP, Rodriguez A, Ramesh N, et al
    Single-cell circulating tumor cell analysis reveals genomic instability as a distinctive feature of aggressive prostate cancer.
    Clin Cancer Res. 2020 Apr 27. pii: 1078-0432.CCR-19-4100.
    PubMed     Abstract available


  55. MANDIGO AC, Knudsen KE
    Double Trouble: Concomitant RB1 and BRCA2 Depletion Evokes Aggressive Phenotypes.
    Clin Cancer Res. 2020;26:1784-1786.
    PubMed     Abstract available


  56. BRAVE M, Weinstock C, Brewer JR, Chi DC, et al
    An FDA Review of Drug Development in Non-Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Apr 13. pii: 1078-0432.CCR-19-3835.
    PubMed     Abstract available


    March 2020
  57. SOKOLOVA AO, Yu EY, Cheng HH
    Honing in on PARPi response in Prostate Cancer: from HR pathway- to gene-by-gene granularity.
    Clin Cancer Res. 2020 Mar 31. pii: 1078-0432.CCR-20-0707.
    PubMed     Abstract available


  58. STOPSACK KH, Nandakumar S, Wibmer AG, Haywood S, et al
    Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer.
    Clin Cancer Res. 2020 Mar 27. pii: 1078-0432.CCR-20-0168.
    PubMed     Abstract available


  59. OBRADOVIC AZ, Dallos M, Zahurak ML, Partin AW, et al
    T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer.
    Clin Cancer Res. 2020 Mar 15. pii: 1078-0432.CCR-19-3372.
    PubMed     Abstract available


  60. BHARGAVA HK, Leo P, Elliott R, Janowczyk A, et al
    Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients.
    Clin Cancer Res. 2020 Mar 5. pii: 1078-0432.CCR-19-2659.
    PubMed     Abstract available


  61. WEI JJ, Wu X, Peng Y, Shi G, et al
    Editor's Note: Regulation of HMGA1 Expression by MicroRNA-296 Affects Prostate Cancer Growth and Invasion.
    Clin Cancer Res. 2020;26:1200.
    PubMed    


    February 2020
  62. FREEDLAND SJ, Allen J, Jarman A, Oyekunle T, et al
    A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2).
    Clin Cancer Res. 2020 Feb 27. pii: 1078-0432.CCR-19-3873.
    PubMed     Abstract available


  63. ABIDA W, Campbell D, Patnaik A, Shapiro JD, et al
    Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study.
    Clin Cancer Res. 2020 Feb 21. pii: 1078-0432.CCR-20-0394.
    PubMed     Abstract available


  64. SZTUPINSZKI Z, Diossy M, Krzystanek M, Borcsok J, et al
    Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations.
    Clin Cancer Res. 2020 Feb 18. pii: 1078-0432.CCR-19-2135.
    PubMed     Abstract available


    January 2020
  65. FAISAL FA, Murali S, Kaur H, Vidotto T, et al
    CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-1669.
    PubMed     Abstract available


  66. CORN PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, et al
    A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naive Metastatic Prostate Cancer.
    Clin Cancer Res. 2020 Jan 15. pii: 1078-0432.CCR-19-2389.
    PubMed     Abstract available


  67. AGARWAL N, Nussenzveig RH, Hahn AW, Hoffman JM, et al
    Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Jan 14. pii: 1078-0432.CCR-19-2591.
    PubMed     Abstract available


  68. LI Y, Yang R, Henzler CM, Ho Y, et al
    Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.
    Clin Cancer Res. 2020 Jan 13. pii: 1078-0432.CCR-19-3023.
    PubMed     Abstract available


  69. NOURI M, Massah S, Caradec J, Lubik AA, et al
    Transient Sox9 Expression Facilitates Progression to Castrate Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Jan 9. pii: 1078-0432.CCR-19-0098.
    PubMed     Abstract available


  70. SCHWEIZER MT, Yu EY
    "Matching" the "mismatch" repair deficient prostate cancer with immunotherapy.
    Clin Cancer Res. 2020 Jan 3. pii: 1078-0432.CCR-19-3780.
    PubMed     Abstract available


  71. SHANKAR S, Ganapathy S, Srivastava RK
    Editor's Note: Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis.
    Clin Cancer Res. 2020;26:312.
    PubMed    


    December 2019
  72. HAMMER S, Hagemann UB, Zitzmann-Kolbe S, Larsen A, et al
    Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer.
    Clin Cancer Res. 2019 Dec 12. pii: 1078-0432.CCR-19-2268.
    PubMed     Abstract available


  73. CORELLA AN, Cabiliza Ordonio MVA, Coleman I, Lucas JM, et al
    Identification of Therapeutic Vulnerabilities in Small Cell Neuroendocrine Prostate Cancer.
    Clin Cancer Res. 2019 Dec 5. pii: 1078-0432.CCR-19-0775.
    PubMed     Abstract available


  74. CHAKRABORTY G, Armenia J, Mazzu YZ, Nandakumar S, et al
    Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression.
    Clin Cancer Res. 2019 Dec 3. pii: 1078-0432.CCR-19-1570.
    PubMed     Abstract available


  75. CHEN K, Cao Q, Song Z, Ruan H, et al
    Targeting the KIF4A/AR axis to reverse endocrine therapy resistance in castration-resistant prostate cancer.
    Clin Cancer Res. 2019 Dec 3. pii: 1078-0432.CCR-19-0396.
    PubMed     Abstract available


    November 2019
  76. ALLOTT EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, et al
    Statin use is associated with lower risk of PTEN-null and lethal prostate cancer.
    Clin Cancer Res. 2019 Nov 21. pii: 1078-0432.CCR-19-2853.
    PubMed     Abstract available


  77. RITCH E, Fu SYF, Herberts C, Wang G, et al
    Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer.
    Clin Cancer Res. 2019 Nov 19. pii: 1078-0432.CCR-19-1623.
    PubMed     Abstract available


  78. GLUMAC PM, Gallant JP, Shapovalova M, Li Y, et al
    Exploitation of CD133 for the targeted imaging of lethal prostate cancer.
    Clin Cancer Res. 2019 Nov 15. pii: 1078-0432.CCR-19-1659.
    PubMed     Abstract available


    October 2019
  79. TAGAWA ST, Antonarakis ES, Gjyrezi A, Galletti G, et al
    Clinical Significance of AR-V567es in Prostate Cancer-Response.
    Clin Cancer Res. 2019;25:6010-6011.
    PubMed    


  80. UO T, Plymate SR
    Clinical Significance of AR-V567es in Prostate Cancer-Letter.
    Clin Cancer Res. 2019;25:6009.
    PubMed    


    September 2019
  81. SPRATT DE, Alshalalfa M, Fishbane N, Weiner AB, et al
    Transcriptomic heterogeneity of androgen receptor (AR) activity defines a de novo low AR-active subclass in treatment naive primary prostate cancer.
    Clin Cancer Res. 2019 Sep 12. pii: 1078-0432.CCR-19-1587.
    PubMed     Abstract available


  82. FENDLER WP, Weber M, Iravani A, Hofman MS, et al
    Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2019 Sep 11. pii: 1078-0432.CCR-19-1050.
    PubMed     Abstract available


  83. PONNUSAMY S, He Y, Hwang DJ, Thiyagarajan T, et al
    Orally-Bioavailable Androgen Receptor Degrader, A Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
    Clin Cancer Res. 2019 Sep 3. pii: 1078-0432.CCR-19-1458.
    PubMed     Abstract available


    August 2019
  84. LIU B, Li L, Yang G, Geng C, et al
    PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2019 Aug 22. pii: 1078-0432.CCR-19-0317.
    PubMed     Abstract available


  85. BHAGIRATH D, Yang TL, Tabatabai ZL, Majid S, et al
    BRN4 is a novel driver of neuroendocrine differentiation in castration-resistant prostate cancer and is selectively released in extracellular vesicles with BRN2.
    Clin Cancer Res. 2019 Aug 1. pii: 1078-0432.CCR-19-0498.
    PubMed     Abstract available


    July 2019
  86. BELTRAN H, Hruszkewycz A, Scher HI, Hildesheim J, et al
    The role of lineage plasticity in prostate cancer therapy resistance.
    Clin Cancer Res. 2019 Jul 30. pii: 1078-0432.CCR-19-1423.
    PubMed     Abstract available


  87. KOTHARI V, Goodwin JF, Zhao SG, Drake JM, et al
    DNA-dependent protein kinase drives prostate cancer progression through transcriptional regulation of the Wnt signaling pathway.
    Clin Cancer Res. 2019 Jul 2. pii: 1078-0432.CCR-18-2387.
    PubMed     Abstract available


    May 2019
  88. SLOVIN SF, Hussain S, Saad F, Garcia JA, et al
    Pharmacodynamic and clinical results from a phase 1/2 study of the HSP90 inhibitor onalespib in combination with abiraterone acetate in prostate cancer.
    Clin Cancer Res. 2019 May 21. pii: 1078-0432.CCR-18-3212.
    PubMed     Abstract available


  89. KULP SK, Chen CS, Wang DS, Chen CY, et al
    Retraction: Antitumor Effects of a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer.
    Clin Cancer Res. 2019;25:2940.
    PubMed    


    April 2019
  90. MAZZU YZ, Armenia J, Chakraborty G, Yoshikawa Y, et al
    A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2).
    Clin Cancer Res. 2019 Apr 17. pii: 1078-0432.CCR-18-4046.
    PubMed     Abstract available


  91. WEST JB, Dinh MN, Brown JS, Zhang J, et al
    Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: An evolution-based strategy.
    Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-19-0006.
    PubMed     Abstract available


  92. BERNEMANN C, Humberg V, Thielen B, Steinestel J, et al
    Comparative analysis of AR variant AR-V567es mRNA detection systems reveals eminent variability and questions the role as a clinical biomarker in prostate cancer.
    Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-18-4276.
    PubMed     Abstract available


  93. FERRARI AC, Alumkal JJ, Stein MN, Taplin ME, et al
    Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2019;25:2672.
    PubMed    


  94. LIU YN, Niu S, Chen WY, Zhang Q, et al
    Leukemia inhibitory factor promotes castration-resistant prostate cancer and neuroendocrine differentiation by activated ZBTB46.
    Clin Cancer Res. 2019 Apr 8. pii: 1078-0432.CCR-18-3239.
    PubMed     Abstract available


    March 2019
  95. KREGEL S, Malik R, Asangani IA, Wilder-Romans K, et al
    Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2019 Mar 27. pii: 1078-0432.CCR-18-3776.
    PubMed     Abstract available


  96. REBELLO RJ, Oing C, Gillessen S, Bristow RG, et al
    TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?
    Clin Cancer Res. 2019;25:1699-1701.
    PubMed     Abstract available


  97. DEHM SM, Montgomery B, Plymate SR
    AR-Variant-Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?
    Clin Cancer Res. 2019;25:1696-1698.
    PubMed     Abstract available


    February 2019
  98. BJARTELL A
    New hope in prostate cancer precision medicine? miRNA replacement and epigenetics.
    Clin Cancer Res. 2019 Feb 26. pii: 1078-0432.CCR-19-0061.
    PubMed     Abstract available


  99. URABE F, Matsuzaki J, Yamamoto Y, Kimura T, et al
    Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer.
    Clin Cancer Res. 2019 Feb 26. pii: 1078-0432.CCR-18-2849.
    PubMed     Abstract available


    January 2019
  100. MOHAMMADPOUR H, Bucsek MJ, Hylander BL, Repasky EA, et al
    Depression stresses the immune response and promotes prostate cancer growth.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-3980.
    PubMed     Abstract available


  101. ZHANG M, Kobayashi N, Zettlitz KA, Kono EA, et al
    Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models.
    Clin Cancer Res. 2019;25:188-200.
    PubMed     Abstract available


    December 2018
  102. BHATIA V, Yadav A, Tiwari R, Nigam S, et al
    Epigenetic silencing of miRNA-338-5p and miRNA-421 drives SPINK1-positive prostate cancer.
    Clin Cancer Res. 2018 Dec 26. pii: 1078-0432.CCR-18-3230.
    PubMed     Abstract available


  103. MOSTAGHEL EA
    Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer.
    Clin Cancer Res. 2018 Dec 10. pii: 1078-0432.CCR-18-3410.
    PubMed     Abstract available


    November 2018
  104. CHENG Y, Tang X, Li Y, Zhao D, et al
    Depression induced neuropeptide Y secretion promotes prostate cancer growth by recruiting myeloid cells.
    Clin Cancer Res. 2018 Nov 30. pii: 1078-0432.CCR-18-2912.
    PubMed     Abstract available


    October 2018
  105. VAISHAMPAYAN U, Podgorski I, Heilbrun LK, Lawhorn-Crews JM, et al
    Biomarkers and Bone Imaging Dynamics associated with Clinical outcomes of Oral Cabozantinib Therapy in Metastatic Castrate Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-1473.
    PubMed     Abstract available


  106. GARRIDO MF, Martin NJ, Bertrand M, Gaudin C, et al
    Regulation of eIF4F translation initiation complex by the peptidyl prolyl isomerase FKBP7 in taxane-resistant prostate cancer.
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-0704.
    PubMed     Abstract available


  107. PAKARAINEN T, Nevalainen J, Talala K, Taari K, et al
    The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC).
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-1807.
    PubMed     Abstract available


  108. TAGAWA ST, Antonarakis ES, Gjyrezi A, Galletti G, et al
    Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY.
    Clin Cancer Res. 2018 Oct 9. pii: 1078-0432.CCR-18-0320.
    PubMed     Abstract available


  109. FLORES-MORALES A, Bergmann TB, Lavallee C, Batth TS, et al
    Proteogenomic characterization of patient-derived xenografts highlights the role of REST in neuroendocrine differentiation of castration-resistant prostate cancer.
    Clin Cancer Res. 2018 Oct 1. pii: 1078-0432.CCR-18-0729.
    PubMed     Abstract available


    September 2018
  110. NAVA RODRIGUES D, Casiraghi N, Romanel A, Crespo M, et al
    RB1 Heterogeneity in Advanced Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Sep 26. pii: 1078-0432.CCR-18-2068.
    PubMed     Abstract available


  111. BELTRAN H, Oromendia C, Danila DC, Montgomery B, et al
    A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers.
    Clin Cancer Res. 2018 Sep 19. pii: 1078-0432.CCR-18-1912.
    PubMed     Abstract available


  112. GAO X, Dai C, Huang S, Tang J, et al
    Functional silencing of HSD17B2 in prostate cancer promotes disease progression.
    Clin Cancer Res. 2018 Sep 18. pii: 1078-0432.CCR-18-2392.
    PubMed     Abstract available


  113. FERRARI AC, Alumkal JJ, Stein MN, Taplin ME, et al
    Epigenetic Therapy with Panobinostat Combined with Bicalutamide Re-challenge in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Sep 17. pii: 1078-0432.CCR-18-1589.
    PubMed     Abstract available


  114. DE LAERE B, Oeyen S, Mayrhofer M, Whitington T, et al
    TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2018 Sep 12. pii: 1078-0432.CCR-18-1943.
    PubMed     Abstract available


  115. ZHANG T, George DJ, Armstrong AJ
    Precision medicine approaches when prostate cancer Akts up.
    Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-2491.
    PubMed     Abstract available


  116. KULARATNE SA, Thomas M, Myers CH, Gagare P, et al
    Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery for Prostate Cancer.
    Clin Cancer Res. 2018 Sep 10. pii: 1078-0432.CCR-18-0803.
    PubMed     Abstract available


  117. ROSATI R, Polin LA, Ducker C, Li J, et al
    Strategy for Tumor Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
    Clin Cancer Res. 2018 Sep 5. pii: 1078-0432.CCR-18-0982.
    PubMed     Abstract available


  118. SIPEKY C, Gao P, Zhang Q, Wang L, et al
    Synergistic interaction of HOXB13 and CIP2A predispose to aggressive prostate cancer.
    Clin Cancer Res. 2018 Sep 4. pii: 1078-0432.CCR-18-0444.
    PubMed     Abstract available


  119. MOSTAGHEL EA, Zhang A, Hernandez S, Marck B, et al
    Contribution of Adrenal Glands to Intra-tumor Androgens and Growth of Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Sep 4. pii: 1078-0432.CCR-18-1431.
    PubMed     Abstract available


    August 2018
  120. GRUBMULLER B, Baltzer PA, Hartenbach S, D'Andrea D, et al
    PSMA ligand PET/MRI for primary prostate cancer: Staging performance and clinical impact.
    Clin Cancer Res. 2018 Aug 23. pii: 1078-0432.CCR-18-0768.
    PubMed     Abstract available


  121. LAMBROS MB, Seed G, Sumanasuriya S, Gil V, et al
    Single Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.
    Clin Cancer Res. 2018 Aug 9. pii: 1078-0432.CCR-18-0862.
    PubMed     Abstract available


  122. GANAIE A, Beigh FH, Astone M, Ferrari MG, et al
    BMI1 drives metastasis of prostate cancer in Caucasian and African-American men and is a potential therapeutic target: hypothesis tested in race-specific models.
    Clin Cancer Res. 2018 Aug 7. pii: 1078-0432.CCR-18-1394.
    PubMed     Abstract available


  123. BARBER LE, Gerke T, Markt SC, Peisch SF, et al
    Family history of breast or prostate cancer and prostate cancer risk.
    Clin Cancer Res. 2018 Aug 6. pii: 1078-0432.CCR-18-0370.
    PubMed     Abstract available


  124. BOYSEN G, Nava Rodrigues D, Rescigno P, Seed G, et al
    SPOP mutated/ CHD1 deleted lethal prostate cancer and abiraterone sensitivity.
    Clin Cancer Res. 2018 Aug 1. pii: 1078-0432.CCR-18-0937.
    PubMed     Abstract available


    July 2018
  125. IGLESIAS-GATO D, Thysell E, Tyanova S, Crnalic S, et al
    The proteome of prostate cancer bone metastasis reveals heterogeneity with prognostic implications.
    Clin Cancer Res. 2018 Jul 24. pii: 1078-0432.CCR-18-1229.
    PubMed     Abstract available


  126. DE BONO JS, De Giorgi U, Nava Rodrigues D, Massard C, et al
    Randomized Phase II Study of Akt Blockade With or Without Ipatasertib in Abiraterone-Treated Patients With Metastatic Prostate Cancer With and Without PTEN Loss.
    Clin Cancer Res. 2018 Jul 23. pii: 1078-0432.CCR-18-0981.
    PubMed     Abstract available


  127. TOREN P, Hoffman A, Ding K, Joncas FH, et al
    Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: a post-hoc analysis of the PR.7 trial.
    Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-1187.
    PubMed     Abstract available


  128. ARAI S, Jonas O, Whitman M, Corey E, et al
    Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
    Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-0549.
    PubMed     Abstract available


  129. LIU Q, Tong D, Liu G, Gao J, et al
    Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration.
    Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-18-0420.
    PubMed     Abstract available


  130. GUPTA S, Nordquist LT, Fleming MT, Berry WR, et al
    Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-18-0564.
    PubMed     Abstract available


  131. TANG W, Wallace TA, Yi M, Magi-Galluzzi C, et al
    IFNL4-DeltaG allele is associated with an interferon signature in tumors and survival of African-American men with prostate cancer.
    Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-18-1060.
    PubMed     Abstract available


    June 2018
  132. ANTONARAKIS ES, Small EJ, Petrylak D, Quinn DI, et al
    Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association With Overall Survival.
    Clin Cancer Res. 2018 Jun 1. pii: 1078-0432.CCR-18-0638.
    PubMed     Abstract available


    May 2018
  133. BLEE AM, He Y, Yang Y, Ye Z, et al
    TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer.
    Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-18-0653.
    PubMed     Abstract available


  134. HAYASHI T, Fujita K, Nojima S, Hayashi Y, et al
    High-fat Diet-induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling.
    Clin Cancer Res. 2018 May 18. pii: 1078-0432.CCR-18-0106.
    PubMed     Abstract available


  135. ALSHALALFA M, Karnes RJ, Sharma V, Choeurng V, et al
    Development and validation of a prostate cancer genomic signature that predicts early ADT treatment response following radical prostatectomy.
    Clin Cancer Res. 2018 May 14. pii: 1078-0432.CCR-17-2745.
    PubMed     Abstract available



  136. Correction: Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.
    Clin Cancer Res. 2018;24:2234.
    PubMed    


  137. BHANVADIA RR, VanOpstall C, Brechka H, Barashi NS, et al
    MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.
    Clin Cancer Res. 2018 May 1. pii: 1078-0432.CCR-17-3673.
    PubMed     Abstract available


    April 2018
  138. HUANG H, Wang C, Liu F, Li HZ, et al
    Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-18-0461.
    PubMed     Abstract available


  139. SHIH TC, Liu R, Wu CT, Li X, et al
    Targeting Galectin-1 impairs castration-resistant prostate cancer progression and invasion.
    Clin Cancer Res. 2018 Apr 17. pii: 1078-0432.CCR-18-0157.
    PubMed     Abstract available


  140. GORDEVICIUS J, Krisciunas A, Groot DE, Yip SM, et al
    Cell-free DNA modification dynamics in abiraterone acetate-treated prostate cancer patients.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-18-0101.
    PubMed     Abstract available


    March 2018
  141. SCROGGINS B, Matsuo M, White A, Saito K, et al
    Hyperpolarized [1-(13)C]-pyruvate magnetic resonance spectroscopic imaging of prostate cancer in vivo predicts efficacy of targeting the Warburg effect.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-1957.
    PubMed     Abstract available


  142. WELTI J, Sharp A, Yuan W, Dolling DI, et al
    Targeting bromodomain and extra-terminal (BET) family proteins in castration resistant prostate cancer (CRPC).
    Clin Cancer Res. 2018 Mar 19. pii: 1078-0432.CCR-17-3571.
    PubMed     Abstract available


    February 2018
  143. MARANTO C, Udhane V, Hoang DT, Gu L, et al
    STAT5A/B BLOCKADE SENSITIZES PROSTATE CANCER TO RADIATION THROUGH INHIBITION OF RAD51 AND DNA REPAIR.
    Clin Cancer Res. 2018 Feb 26. pii: 1078-0432.CCR-17-2768.
    PubMed     Abstract available


  144. HECK MM, Retz M, Bandur M, Souchay M, et al
    Molecular lymph node status for prognostic stratification of prostate cancer patients undergoing radical prostatectomy with extended pelvic lymph node dissection.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-3771.
    PubMed     Abstract available


  145. KIM K, Watson PA, Lebdai S, Jebiwott S, et al
    Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-3474.
    PubMed     Abstract available


    November 2017
  146. WANG C, Peng G, Huang H, Liu F, et al
    Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer.
    Clin Cancer Res. 2017 Nov 30. pii: 1078-0432.CCR-17-2446.
    PubMed     Abstract available


  147. YANG Y, Bai Y, He Y, Zhao Y, et al
    PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer.
    Clin Cancer Res. 2017 Nov 22. pii: clincanres.2006.2017.
    PubMed     Abstract available


  148. PUHR M, Hoefer J, Eigentler A, Ploner C, et al
    The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved anti-androgen therapy.
    Clin Cancer Res. 2017 Nov 20. pii: clincanres.0989.2017.
    PubMed     Abstract available


  149. BELDERBOS BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, et al
    Influence of Enzalutamide on Cabazitaxel Pharmacokinetics; a Drug-Drug Interaction Study in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients.
    Clin Cancer Res. 2017 Nov 17. pii: clincanres.2336.2017.
    PubMed     Abstract available


  150. ZHANG W, Liu B, Wu W, Li L, et al
    Targeting the MYCN-PARP-DNA Damage Response Pathway inNeuroendocrine Prostate Cancer.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.1872.2017.
    PubMed     Abstract available


  151. PALLER CJ, Zhou XC, Heath EI, Taplin ME, et al
    Muscadine Grape Skin Extract in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.
    Clin Cancer Res. 2017 Nov 7. pii: clincanres.1100.2017.
    PubMed     Abstract available


    September 2017
  152. KALINA JL, Neilson DS, Lin YY, Hamilton PT, et al
    Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T cell Epitopes & Immune Signatures in a Subset of Prostate Cancer.
    Clin Cancer Res. 2017 Sep 27. pii: clincanres.0618.2017.
    PubMed     Abstract available


  153. LABBE DP, Sweeney CJ, Brown M, Galbo P, et al
    TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.0413.2017.
    PubMed     Abstract available


  154. KETOLA K, Munuganti RS, Davies A, Nip KM, et al
    Targeting Prostate Cancer Subtype 1 by Forkhead box M1 Pathway Inhibition.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.0901.2017.
    PubMed     Abstract available


  155. CALAGUA C, Russo J, Sun Y, Schaefer R, et al
    Expression of PD-L1 in Hormone-naive and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
    Clin Cancer Res. 2017 Sep 11. pii: clincanres.0807.2017.
    PubMed     Abstract available


    August 2017
  156. BELTRAN H, Wyatt AW, Chedgy E, Donoghue A, et al
    Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
    Clin Cancer Res. 2017 Aug 25. pii: clincanres.1034.2017.
    PubMed     Abstract available


  157. GUEDES L, Antonarakis ES, Schweizer MT, Mirkheshti N, et al
    MSH2 Loss in Primary Prostate Cancer.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0955.2017.
    PubMed     Abstract available


    July 2017
  158. GAO WQ, Guo Y, Zhang K, Cheng C, et al
    Numb-/low enriches a castration resistant prostate cancer cell subpopulation associated with enhanced Notch and Hedgehog signaling.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0913.2017.
    PubMed     Abstract available


  159. SEED G, Yuan W, Mateo J, Carreira S, et al
    Gene Copy Number Estimation From Targeted Next Generation Sequencing Of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0972.2017.
    PubMed     Abstract available



  160. Retraction: GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.
    Clin Cancer Res. 2017;23:3973.
    PubMed    



  161. Correction: A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2017;23:3970.
    PubMed    


    June 2017
  162. BILUSIC M, Madan RA, Gulley JL
    Immunotherapy of Prostate Cancer: Facts and Hopes.
    Clin Cancer Res. 2017 Jun 29. pii: clincanres.0019.2017.
    PubMed     Abstract available


  163. XU L, Mao X, Guo T, Chan PY, et al
    The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis.
    Clin Cancer Res. 2017 Jun 14. pii: clincanres.3081.2016.
    PubMed     Abstract available


    May 2017
  164. BAN K, Feng S, Shao L, Ittmann M, et al
    RET signaling in prostate cancer.
    Clin Cancer Res. 2017 May 10. pii: clincanres.0528.2017.
    PubMed     Abstract available


  165. KOHLI M, Ho Y, Hillman DW, Van Etten JL, et al
    Androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance.
    Clin Cancer Res. 2017 May 4. pii: clincanres.0017.2017.
    PubMed     Abstract available


  166. MONTGOMERY B, Tretiakova MS, Joshua AM, Gleave ME, et al
    Neoadjuvant Enzalutamide Prior to Prostatectomy.
    Clin Cancer Res. 2017;23:2169-2176.
    PubMed     Abstract available


    April 2017
  167. GUEDES L, Almutairi F, Haffner MC, Rajoria G, et al
    Analytic, Pre-analytic and Clinical Validation of p53 Immunohistochemistry for Detection of TP53 Missense Mutation in Prostate Cancer.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.0257.2017.
    PubMed     Abstract available


  168. MOSTAGHEL EA, Cho E, Zhang A, Alyamani M, et al
    Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.
    Clin Cancer Res. 2017 Apr 7. pii: clincanres.2245.2016.
    PubMed     Abstract available


  169. NIEUWEBOER AJ, de Graan AM, Hamberg P, Bins S, et al
    Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study.
    Clin Cancer Res. 2017;23:1679-1683.
    PubMed     Abstract available


  170. NESBITT H, Byrne NM, Williams SN, Ming L, et al
    Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.
    Clin Cancer Res. 2017;23:1797-1808.
    PubMed     Abstract available


    March 2017
  171. SUOMINEN MI, Fagerlund KM, Rissanen JP, Konkol YM, et al
    Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models.
    Clin Cancer Res. 2017 Mar 31. pii: clincanres.2955.2016.
    PubMed     Abstract available


    January 2017
  172. SINNOTT JA, Peisch SF, Tyekucheva S, Gerke T, et al
    Prognostic Utility of a New mRNA Expression Signature of Gleason Score.
    Clin Cancer Res. 2017;23:81-87.
    PubMed     Abstract available


    May 2016
  173. CHUA ML, Bristow RG
    Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or <I>Frenemy</I>?
    Clin Cancer Res. 2016 May 10. pii: clincanres.0381.2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: